Oramed Pharmaceuticals (Oramed Pharmaceuticals) Cash And Cash Equivalents : $9.06 Mil (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Oramed Pharmaceuticals Cash And Cash Equivalents?

Oramed Pharmaceuticals's quarterly cash and cash equivalents declined from Jun. 2023 ($6.77 Mil) to Sep. 2023 ($5.47 Mil) but then increased from Sep. 2023 ($5.47 Mil) to Dec. 2023 ($9.06 Mil).

Oramed Pharmaceuticals's annual cash and cash equivalents declined from Aug. 2021 ($77.25 Mil) to Dec. 2022 ($40.46 Mil) and declined from Dec. 2022 ($40.46 Mil) to Dec. 2023 ($9.06 Mil).

Oramed Pharmaceuticals Cash And Cash Equivalents Historical Data

The historical data trend for Oramed Pharmaceuticals's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oramed Pharmaceuticals Cash And Cash Equivalents Chart

Oramed Pharmaceuticals Annual Data

Trend

Aug14

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

3.33

19.30

77.25

40.46

9.06

Oramed Pharmaceuticals Quarterly Data
	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															40.46	24.10	6.77	5.47	9.06

Oramed Pharmaceuticals Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Oramed Pharmaceuticals (NAS:ORMP) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Oramed Pharmaceuticals Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Oramed Pharmaceuticals's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Oramed Pharmaceuticals (Oramed Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oramed Pharmaceuticals Inc (NAS:ORMP) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

OJU1:Germany

Address

1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036

Website

https://www.oramed.com

Oramed Pharmaceuticals Inc is a pharmaceutical company which is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The ORMD-0801 is a proprietary product which is an orally ingestible insulin capsule for the treatment of diabetes. Its other product includes Oral Glucagon-like peptide-1 which is an incretin hormone, a type of gastrointestinal hormone that stimulates the secretion of insulin from the pancreas.

Executives

Benjamin Shapiro	director	1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Nadav Kidron	director, 10 percent owner	142 W. 57TH ST., NEW YORK NY 10019
Yadin Rozov	director	9 TERRACE CIRCLE, ARMONK NY 10504
Miriam Kidron	director	2 ELZA STREET, JERUSALEM L3 93706
Michael Rabinowitz	officer: Chief Commercial Officer	1185 AVENUE OF THE AMERICAS, THIRD FLOOR, NEW YORK NY 10036
Arie Mayer	director	MORAN 16, KFAR SABA L3 4428890
Netanel Derovan	officer: Chief Legal Officer	1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
David Silberman	officer: Chief Financial Officer	20 MAMILLA AVENUE, JERUSALEM L3 9414904
Kevin Rakin	director	36 CHURCH LANE, WESTPORT CT 06880
Michael Rabinowitz	officer: Chief Commercial Officer	MAXIM GROUP, LLC, 405 LEXINGTON AVENUE, NEW YORK NY 10174
Leonard Sank	director	3 BLAIR ROAD, CAPE TOWN T3 8005
Gao Xiaoming	director	11F. NO. 266 HANKOU ROAD, HUANGPU DISTRICT, SHANGHAI F4 2000001
Avraham Gabay	officer: CFO, Treasurer and Secretary	2/4 HIGH-TECH PARK, P.O. BOX 39098, JERUSALEM L3 91390
Mark Daniel Hasleton	officer: VP Business Development	13, HIBAT ZION, RAANANA, RAANANA L3 4338111
Aviad Friedman	director	HADASSA 6, TEL AVIV L3 6451306